News:
Sept. 11, 2024 – Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody™ Platform
Dec. 20, 2023 – Radiant to Assess Multi-Valent, Multi-Specific Multabodies as Potential Treatments for HIV
Investors:
